Upstream Bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
UPB Nasdaq 2834 upstreambio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Upstream Bio, Inc.

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 - Sep 8th, 2026 1:30 am
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027 - Sep 1st, 2026 5:31 am
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - Sep 1st, 2026 5:00 am
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Aug 11th, 2026 6:35 am
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress - Aug 11th, 2026 5:00 am
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Jul 14th, 2026 10:00 am
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? - Jun 25th, 2026 6:42 am
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? - Jun 23rd, 2026 9:36 am
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 - Jun 14th, 2026 8:00 am
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - Jun 8th, 2026 5:00 am
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 3rd, 2026 5:00 am
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - May 18th, 2026 9:30 am
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - May 13th, 2026 6:20 am
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 13th, 2026 5:00 am
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - Apr 17th, 2026 5:00 am
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 26th, 2026 5:00 am
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight - Mar 5th, 2026 3:31 pm
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting - Mar 1st, 2026 7:45 am
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Feb 26th, 2026 5:00 am